Difference between revisions of "Messenger RNA Vaccine"

From MIT Technology Roadmapping
Jump to navigation Jump to search
Line 1: Line 1:
=Roadmap Overview=
= Roadmap Overview =
Roadmap Overview of mRNA Vaccine Technology
'''Roadmap Overview of mRNA Vaccine Technology'''


1. Discovery (DCY)
== Discovery (DCY) ==
- The initial phase focuses on identifying and understanding the genetic composition of the target virus and creating a blueprint for the mRNA vaccine.
* The initial phase focuses on identifying and understanding the genetic composition of the target virus and creating a blueprint for the mRNA vaccine.
- SVI: Structural inference from viral nucleotide information
** '''SVI''': Structural inference from viral nucleotide information
- MRD: mRNA design
** '''MRD''': mRNA design
- MRS: mRNA Synthesis
** '''MRS''': mRNA Synthesis
- MRM: mRNA modification
** '''MRM''': mRNA modification
- LMS: Lipid Membrane Synthesis
** '''LMS''': Lipid Membrane Synthesis


2. Development (DVT)
== Development (DVT) ==
- This stage involves testing the designed vaccine in human trials and ensuring its safety and efficacy.
* This stage involves testing the designed vaccine in human trials and ensuring its safety and efficacy.
- RMH: Risk Management of the Human Body
** '''RMH''': Risk Management of the Human Body
- CTM: Clinical Trial Management
** '''CTM''': Clinical Trial Management


3. Manufacturing Process (MFP)
== Manufacturing Process (MFP) ==
- Once approved, the vaccine goes into mass production, ensuring that each component is assembled accurately and in the required quantities.
* Once approved, the vaccine goes into mass production, ensuring that each component is assembled accurately and in the required quantities.
- MMS: mRNA mass synthesis (scale-up)
** '''MMS''': mRNA mass synthesis (scale-up)
- MLS: Massive lipid synthesis
** '''MLS''': Massive lipid synthesis
- MSB: Mass synthesis of buffers and other excipients
** '''MSB''': Mass synthesis of buffers and other excipients
- MVA: Mass vaccine assembly
** '''MVA''': Mass vaccine assembly


4. Actual Vaccination Situation
== Actual Vaccination Situation ==
- This final stage involves the distribution and administration of the vaccine to individuals, ensuring that they gain immunity.
* This final stage involves the distribution and administration of the vaccine to individuals, ensuring that they gain immunity.
- (No specific sub-processes are provided for this step)
(Note: No specific sub-processes are provided for this step)


Vaccine Development Technologies (1VDT)
== Vaccine Development Technologies (1VDT) ==
- LAV: Live-attenuated vaccines
* '''LAV''': Live-attenuated vaccines
- IAV: Inactivated vaccines
* '''IAV''': Inactivated vaccines
- SUV: Subunit vaccines
* '''SUV''': Subunit vaccines
- TXV: Toxoid vaccines
* '''TXV''': Toxoid vaccines
- VVV: Viral vector vaccines
* '''VVV''': Viral vector vaccines
- MRV: Messenger RNA (mRNA) vaccine
* '''MRV''': Messenger RNA (mRNA) vaccine


This roadmap gives a structured overview of the mRNA vaccine technology, breaking down each phase into specific processes and tasks. Each step is crucial to ensuring the safety, efficacy, and availability of the vaccine to the masses.
'''Note''': This roadmap gives a structured overview of the mRNA vaccine technology, breaking down each phase into specific processes and tasks. Each step is crucial to ensuring the safety, efficacy, and availability of the vaccine to the masses.


=Design Structure Matrix (DSM) Allocation=
=Design Structure Matrix (DSM) Allocation=

Revision as of 23:43, 11 October 2023

Roadmap Overview

Roadmap Overview of mRNA Vaccine Technology

Discovery (DCY)

  • The initial phase focuses on identifying and understanding the genetic composition of the target virus and creating a blueprint for the mRNA vaccine.
    • SVI: Structural inference from viral nucleotide information
    • MRD: mRNA design
    • MRS: mRNA Synthesis
    • MRM: mRNA modification
    • LMS: Lipid Membrane Synthesis

Development (DVT)

  • This stage involves testing the designed vaccine in human trials and ensuring its safety and efficacy.
    • RMH: Risk Management of the Human Body
    • CTM: Clinical Trial Management

Manufacturing Process (MFP)

  • Once approved, the vaccine goes into mass production, ensuring that each component is assembled accurately and in the required quantities.
    • MMS: mRNA mass synthesis (scale-up)
    • MLS: Massive lipid synthesis
    • MSB: Mass synthesis of buffers and other excipients
    • MVA: Mass vaccine assembly

Actual Vaccination Situation

  • This final stage involves the distribution and administration of the vaccine to individuals, ensuring that they gain immunity.

(Note: No specific sub-processes are provided for this step)

Vaccine Development Technologies (1VDT)

  • LAV: Live-attenuated vaccines
  • IAV: Inactivated vaccines
  • SUV: Subunit vaccines
  • TXV: Toxoid vaccines
  • VVV: Viral vector vaccines
  • MRV: Messenger RNA (mRNA) vaccine

Note: This roadmap gives a structured overview of the mRNA vaccine technology, breaking down each phase into specific processes and tasks. Each step is crucial to ensuring the safety, efficacy, and availability of the vaccine to the masses.

Design Structure Matrix (DSM) Allocation

The DSM illustrates the interplay between the tools and methods that constitute the Messenger RNA Vaccine. A 'X' sign denotes that the techniques are interconnected.

Error creating thumbnail: File with dimensions greater than 12.5 MP

Roadmap Model using OPM

Discovery

The discovery process spans from obtaining the genetic information of the target virus to the phase just before the commencement of human clinical trials.

OPM1

Development

The development process begins with the first human clinical trial and continues until the drug receives approval. OPM2

Manufacturing process

The manufacturing process begins after the drug has been approved. It starts with the assembly of each ingredient component and continues through to the shipment of the finished vaccine products.

OPM3

Actual Vaccination Situation

The Actual Vaccination Situation refers to the process that starts with receiving the vaccine products at the vaccination site and culminates in individuals gaining immunity after being administered the vaccines.

OPM4

Figures of Merit

XXX

Alignment with Company Strategic Drivers

XXX

Positioning of Company vs. Competition

XXX

Technical Model

XXX

Financial Model

XXX

Retrieved from "https://roadmaps.mit.edu/index.php?title=Messenger_RNA_Vaccine&oldid=113280"